amphastar pharmaceuticals, inc., headquartered in rancho cucamonga, california, established in 1996, is a recognized specialty pharmaceutical company that uses state-of-the-art, cgmp compliant facilities to develop, manufacture, and market injectable and inhalation products. in addition to the corporate headquarters, amphastar has five manufacturing facilities located in the united states, china and europe along with a state-of-the-art new drug research center. amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. we currently produce approximately 15 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the u.s. enables it to establish significant market share upon the int
Company profile
Ticker
AMPH
Exchange
Website
CEO
Jack Zhang
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
International Medication Systems, Limited • Amphastar Medication Co., LLC • Armstrong Pharmaceuticals, Inc. • Amphastar Nanjing Pharmaceuticals, Inc. • Amphastar France Pharmaceuticals, S.A.S. • Amphastar UK Limited • International Medication Systems (UK) Limited ...
AMPH stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
12 Apr 24
DEFA14A
Additional proxy soliciting materials
12 Apr 24
DEF 14A
Definitive proxy
12 Apr 24
S-8
Registration of securities for employees
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023
28 Feb 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2023
8 Nov 23
8-K
Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes
15 Sep 23
8-K/A
Abbreviated Financial Statements
16 Aug 23
Transcripts
AMPH
Earnings call transcript
2023 Q4
28 Feb 24
AMPH
Earnings call transcript
2023 Q3
8 Nov 23
AMPH
Earnings call transcript
2023 Q2
8 Aug 23
AMPH
Earnings call transcript
2023 Q1
9 May 23
AMPH
Earnings call transcript
2022 Q4
28 Feb 23
AMPH
Earnings call transcript
2022 Q3
8 Nov 22
AMPH
Earnings call transcript
2022 Q2
9 Aug 22
AMPH
Earnings call transcript
2022 Q1
9 May 22
AMPH
Earnings call transcript
2021 Q4
11 Mar 22
AMPH
Earnings call transcript
2021 Q3
9 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
79.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 250 |
Opened positions | 41 |
Closed positions | 32 |
Increased positions | 89 |
Reduced positions | 89 |
13F shares | Current |
---|---|
Total value | 1.46 tn |
Total shares | 38.81 mm |
Total puts | 24.90 k |
Total calls | 24.30 k |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
Jack Y. Zhang | 6.83 mm | $0.00 |
BLK Blackrock | 6.09 mm | $280.09 bn |
FHI Federated Hermes Inc - Ordinary Shares | 3.44 mm | $158.31 bn |
Vanguard | 2.77 mm | $127.27 bn |
Dimensional Fund Advisors | 1.89 mm | $86.82 bn |
Neuberger Berman | 1.49 mm | $68.43 bn |
STT State Street | 1.46 mm | $67.12 bn |
Fuller & Thaler Asset Management | 1.28 mm | $58.65 bn |
Geode Capital Management | 809.63 k | $37.24 bn |
Renaissance Technologies | 603.10 k | $27.72 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Floyd F. Petersen | Common Stock | Sell | Dispose S | No | Yes | 43.4283 | 500 | 21.71 k | 79,333 |
17 Mar 24 | Jack Y. Zhang | Common Stock | Payment of exercise | Dispose F | Yes | No | 43.05 | 7,052 | 303.59 k | 1,229,756 |
17 Mar 24 | Jack Y. Zhang | Common Stock | Payment of exercise | Dispose F | No | No | 43.05 | 15,768 | 678.81 k | 2,433,554 |
17 Mar 24 | Liawatidewi Yakob | Common Stock | Payment of exercise | Dispose F | No | No | 43.05 | 1,726 | 74.30 k | 74,778 |
17 Mar 24 | Zhou Rong | Common Stock | Payment of exercise | Dispose F | No | No | 43.05 | 1,961 | 84.42 k | 118,016 |
17 Mar 24 | Peters William J | Common Stock | Payment of exercise | Dispose F | No | No | 43.05 | 4,255 | 183.18 k | 97,655 |
16 Mar 24 | Liawatidewi Yakob | Common Stock | Payment of exercise | Dispose F | No | No | 43.05 | 1,671 | 71.94 k | 76,504 |
16 Mar 24 | Zhou Rong | Common Srock | Payment of exercise | Dispose F | No | No | 43.05 | 2,355 | 101.38 k | 119,977 |
16 Mar 24 | Peters William J | Common Stock | Payment of exercise | Dispose F | No | No | 43.05 | 5,105 | 219.77 k | 101,910 |
15 Mar 24 | Jack Y. Zhang | Common Stock | Payment of exercise | Dispose F | Yes | No | 43.05 | 202,658 | 8.72 mm | 1,236,808 |
News
Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies
10 Apr 24
Needham Reiterates Hold on Amphastar Pharma
10 Apr 24
JP Morgan Initiates Coverage On Amphastar Pharma with Overweight Rating, Announces Price Target of $60
5 Mar 24
Amphastar Pharma Q4 EPS $0.88 Misses $0.91 Estimate, Sales $178.10M Beat $175.67M Estimate
28 Feb 24
Earnings Scheduled For February 28, 2024
28 Feb 24
Press releases
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023
28 Feb 24
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024
20 Feb 24
What Vitamins Did For Healthy Living, Stemtech Corporation (OTCQB: STEK) Says It Is Doing For Anti-Aging With Stem Cell Nutrition
22 Jan 24